Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05237817

Association Between Stroke and Adrenal Incidentalomas

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Background:

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke . The investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

Objective:

To measure the association between stroke and levels of autonomous cortisol secretion in patients with AIs.

Design:

Part 1, Retrospective cohort study.

From April 1, 2021, to September 30, 2021, cohort patients with stroke were recruited in this study. The investigators assess the standardised incidence rate of AIs in all patients. Meanwhile, detail information about stroke disease、patient and AIs characteristics were record.

Part 2, Prospective cohort study.

From Mar 1, 2022, to Feb 29, 2024, cohort patients with stroke plane to recruit in this study. All patient receive the plasma cortisol level after a 1-mg dexamethasone suppression test. The investigators assess the standardised incidence rate of AIs in all patients. Meanwhile, detail information about stroke disease、patient and AIs characteristics would be record.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • stroke disease , such as Cerebral infarction、Intracerebral hemorrhage and Subarachnoid hemorrhage.

Exclusion criteria

  • presence of metastatic cancer;
  • AIs smaller than 1 cm;
  • nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts;
  • oral glucocorticoid treatment with more than single doses in the past 3 months;
  • use of inhaled steroids or medication affecting dexamethasone metabolism;
  • systemic estrogen treatment.

Treatment and study plan

Primary outcomes

  1. Incidence rate of Adrenal incidentalomas

    Time frame: 5 years

    Assess the standardised incidence rate of AIs in all patients with stroke

  2. Plasma cortisol level

    Time frame: 5 years

    Plasma cortisol level after a 1-mg dexamethasone suppression test

Secondary outcomes

  1. Diameter of Adrenal incidentalomas

    Time frame: 5 years

    Maximal axial diameter of adrenal incidentalomas by computed tomography scan; Millimetre as a metric unit of length in this study

Study contacts

Contact information is provided by the study sponsor or research team.

Hao Yan, Dr.

CONTACT

[email protected]

+86-13651341058

Tong W Ou, Dr.

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Xuanwu Hospital, Beijing

Other

Registry information

Official study title

If Adrenal Incidentalomas Have the Influences to Occur and Progress in Patients With Stroke

Acronym: ABSAI

Important dates

Study start
2021
Primary completion
2022
Study completion
2029
First posted
Feb 14, 2022
Registry last updated
Feb 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.